Comparison · NCT01808092-sae
CAZ-AVI vs Meropenem: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CAZ-AVI vs Meropenem: serious adverse events. Trial comparisons, record NCT01808092-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01808092-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.185 | 0.15 | 0.226 | wilson | |
| Risk in group 2 | 0.134 | 0.104 | 0.171 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0512 | 0.00058 | 0.102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.38 | 1 | 1.91 | log | |
| Odds ratio, group 1 over group 2 | 1.47 | 1 | 2.15 | log | |
| Number needed to harm, for one more participant with a serious adverse event on CAZ-AVI than on Meropenem | 19.5 | 9.84 | 1,720 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CAZ-AVI | 2000mg ceftazidime / 500mg avibactam intravenous (IV) infused over 2 hours plus appropriate placebo to meropenem | 75 | 405 | EG000 |
| Group 2 | Meropenem | meropenem 1000mg IV infused over 30 minutes plus CAZ-AVI placebo | 54 | 403 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Nonserious AEs and SAEs are collected for each patient from date when informed consent is obtained until the date of final protocol follow-up, study withdrawal or date of death from any cause, whichever came first, assessed up to 28 days.
Source ClinicalTrials.gov
Trial
- Title
- A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
- NCT number
- NCT01808092
- Phases
- PHASE3
- Conditions
- Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)
- Interventions
- ceftazidim-avibactam (CAZ-AVI, experimental product), meropenem (active comparator)
- Lead sponsor
- Pfizer
- Results first posted
- 2017-02-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01808092?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01808092-sae